Prior authorization and denial risk for investigational/NMN tests

Tests identified as investigational or not medically necessary (policy examples include CPT 0060U for twin zygosity and CPT 81422 for microdeletion screening) may require prior authorization and are subject to denial if submitted for those indications.

• Example not medically necessary code: CPT 0060U (twin zygosity).
• Example investigational code: CPT 81422 (microdeletion testing).

Prior authorization — contract and documentation required

Genetic testing is contract dependent and may require prior authorization per plan terms; providers should submit documentation supporting medical appropriateness when requesting coverage.

• Coverage only applies to members with a valid contract; family members without a valid contract are not covered.
• Documentation supporting medical appropriateness will be considered when determining coverage.

Prior authorization — not detailed here; confirmatory testing noted

The policy does not specify explicit prior authorization procedures in this section; however, clinical limitations and the need for confirmatory diagnostic testing for high‑risk results are noted and may influence authorization decisions.

• High‑risk NIPT results should be confirmed with diagnostic testing (CVS or amniocentesis).
• Limited evidence in some contexts (e.g., microdeletions, multiples) may affect authorization determinations.

Coverage designation tied to listed molecular assay codes

Certain listed molecular assay CPT/PLA codes are designated as Experimental/Investigational (E/I) or Not Medically Necessary (NMN) in the coding lists and these designations may affect coverage.

• Examples of E/I or NMN designations are provided in the CPT/PLA code listings (see policy coding section).
• E/I or NMN designation may lead to denial or requirement for prior authorization.

Coding may trigger prior authorization per product contract

CPT and PLA codes listed in the policy (including proprietary PLA codes) may require authorization per product contract; investigational or NMN coding designations in the policy can affect coverage determination.

• Providers should verify product-specific authorization requirements before ordering/testing.
• Some PLA codes are labeled NMN or E/I in the policy coding tables.

Preferred validated screening pathway — first‑trimester serum + NT

First‑trimester combined screening using serum analytes plus nuchal translucency ultrasound is described as a medically appropriate screening pathway for trisomy 21, 13, and 18 and is an accepted validated option.

• First‑trimester combined screening (PAPP‑A, free β‑hCG plus NT) is an established pathway for T21/T13/T18 screening.
• If screening is accepted, only one screening should be performed per ACOG/SMFM guidance.

Step requirement: perform targeted testing before panel testing

When a specific syndrome is suspected based on family history or phenotype, targeted mutation testing should be performed and documented prior to ordering broader panel testing unless a rationale for panel testing is provided.

• Document results of targeted testing or provide clinical rationale for panel testing.
• Policy requires documentation when panel testing is chosen over targeted testing.

Traditional screening remains an established context before invasive diagnostics

Traditional serum and ultrasound‑based screening approaches are described as established steps for risk assessment prior to invasive diagnostic testing and remain appropriate options.

• Standard screening combinations of serum markers and fetal ultrasound are routinely offered.
• High‑risk screening results should be confirmed with diagnostic karyotyping after invasive sampling.

Step therapy: none specified

No step therapy sequencing requirements are specified in these policy sections; the policy states that no formal step therapy is applicable.

• Providers should follow clinical guidance and documented criteria when selecting screening tests.
• Contract coverage and test-specific coding designations remain relevant to coverage decisions.

Contract dependency — verify member coverage

Coverage and applicability of services are contract dependent; medical policy criteria apply only when a member's product covers the service.

• Verify that the member's product covers the requested service before ordering.
• If a product does not cover a service, the medical policy criteria do not apply.

Documentation required for fetal RhD cfDNA genotyping

When ordering cfDNA fetal RhD genotyping, documentation must show maternal RhD‑negative status or presence of maternal red cell antigen antibodies and meet the policy's specified criteria for use.

• Document maternal RhD‑negative status or maternal antibodies.
• Document paternal typing is unavailable or heterozygous and that amniocentesis is declined or contraindicated.

Required supporting documentation for medical appropriateness

Provide supporting documentation demonstrating a reasonable expectation of an inherited condition based on family history, pedigree, risk factors, or phenotype when ordering genetic testing; if panel testing is ordered without prior targeted testing, document the rationale.

• Show how test results will impact treatment or medical management.
• Document targeted testing results or rationale for panel testing when a specific syndrome is suspected.

Laboratory and counseling documentation requirement

Genetic testing must be performed by a CLIA‑certified laboratory and be offered in a setting with personnel qualified to provide pre‑ and post‑test genetic counseling.

• Ensure laboratory CLIA certification is documented.
• Provide access to appropriately trained professionals for pre‑ and post‑test counseling.

Confirmatory diagnostic testing required after high‑risk NIPT

When NIPT indicates a high risk for trisomy, confirmatory diagnostic testing (karyotyping from amniocentesis or chorionic villus sampling) is required to establish a diagnosis.

• Order confirmatory CVS or amniocentesis for high‑risk NIPT results prior to definitive clinical decisions.
• Document counseling provided and patient decisions regarding diagnostic testing.

Follow‑up actions after positive or nonreportable cfDNA

After a positive or nonreportable cfDNA result, patients should be offered genetic counseling, a comprehensive ultrasound, and diagnostic testing; document counseling and follow‑up plans.

• Offer genetic counseling and comprehensive ultrasound.
• Offer diagnostic testing and document patient acceptance or decline.

Required diagnosis coding on claims

Use appropriate ICD‑10 diagnosis code ranges on claims for fetal aneuploidy, sex chromosome abnormalities, other autosomal trisomies, marker chromosomes, monosomies/deletions, balanced rearrangements, and antenatal screening/encounters as listed in the policy.

• Examples include code ranges Q90.x, Q91.x, Q92.x, Q95.x, Q96.x‑Q99.x and encounter codes Z31.43x‑Z31.448, Z31.5, Z36.x.
• Ensure diagnosis coding aligns with the clinical indication documented.

Denial risk — NT measurement not covered for chromosomal abnormality detection

Nuchal translucency measurement billed for the purpose of detecting chromosomal abnormalities is not medically necessary under this policy and may result in denial if submitted for that indication.

• NT assessment as a chromosomal abnormality screen is considered not medically necessary per policy.
• Follow first‑trimester combined screening guidance when NT is used in combination with serum analytes.

Denial risk — investigational or NMN NIPT indications

NIPT indications identified as investigational or not medically necessary (including twin zygosity CPT 0060U, multiple gestation screening, aneuploidies other than T21/T13/T18, microdeletions CPT 81422, sex chromosome aneuploidy, and single‑gene disorder screening) may trigger claim denials.

• Twin zygosity (0060U) designated NMN and subject to denial.
• Microdeletion testing (81422) and single‑gene NIPT examples are considered investigational.

Contract dependency — verify member eligibility

Coverage is contract dependent; members without a valid contract are not covered and services should not be provided under this policy for those individuals.

• Verify member eligibility and product coverage before ordering testing.
• Policy criteria apply only when the member's product covers the service.

CNV/microdeletion testing — performance limitations and caution

Copy number variant/microdeletion testing via cfDNA has variable and generally poorer performance, limited confirmatory data, and should be used with caution; this limitation may influence coverage decisions.

• Study sensitivities for microdeletions varied widely and confirmatory testing was often unavailable.
• Documented limitations may lead to restricted coverage or denial for microdeletion testing.

Denial risk — limited evidence in multiple gestations

Evidence for cfDNA utility in multiple gestations is limited; lack of direct evidence of improved net health outcome in multiples may result in denial or restriction of coverage.

• Studies in multiples are fewer and lack sufficient follow‑up to determine performance fully.
• Providers should expect possible coverage restrictions for multifetal pregnancies.

Coding‑based denial risk — verify code coverage applicability

Codes listed in the policy coding sections may not be covered under all circumstances; using these CPT/PLA/HCPCS codes for investigational or non‑covered indications may lead to claim denials.

• Review policy coding designations (E/I, NMN) before submitting claims.
• Some proprietary PLA codes are explicitly labeled NMN or E/I in the coding table.

Investigational test denial risk (proprietary assays)

Tests or specific proprietary assays designated investigational (policy example: Vasistera for single‑gene disorders and certain PLA codes labeled NMN) may be denied when submitted for investigational indications.

• Policy revisions note removal of Vasistera as an example for single‑gene testing and its investigational designation.
• Investigational designation in the coding list may result in denial for those indications.

Offer NIPT with informed consent and qualified counseling

Offer NIPT only in the context of informed consent, education, and counseling by a qualified provider (for example, a certified genetic counselor); ensure counseling is documented.

• Provide pre‑test informed consent and education prior to ordering NIPT.
• Document counseling and the patient's informed decision in the medical record.

Counseling and informed consent required and documented

Emphasize pre‑ and post‑test counseling and informed consent for NIPT; counseling should be provided by a qualified professional and documented in the record.

• Ensure availability of personnel qualified to provide pre‑ and post‑test counseling.
• Document counseling content and patient decisions regarding diagnostic confirmation if indicated.

Recommend confirmatory diagnostic testing and counseling after high‑risk NIPT

Confirmatory diagnostic testing (CVS or amniocentesis with karyotype) is recommended when NIPT indicates high risk for aneuploidy; provide genetic counseling alongside confirmatory testing.

• Do not treat NIPT as diagnostic—order invasive diagnostic testing to confirm high‑risk results.
• Document counseling, diagnostic testing results, and subsequent management.

NIPT must be offered with counseling by qualified personnel

Offer NIPT with informed consent and counseling by qualified personnel and ensure documentation of counseling and informed decision‑making in the medical record.

• Qualified personnel include certified genetic counselors or other trained providers.
• Document the informed consent discussion in the record prior to testing.

Counseling and informed consent — documentation emphasized

Counseling and informed consent are required; ensure counseling is available and recorded in the clinical record.

• Pre‑test education and informed consent must be documented.
• Post‑test counseling should be documented, particularly for abnormal or nonreportable results.

Document genetic counseling encounters (Z31.5 referenced)

Policy references encounter code Z31.5 for procreative genetic counseling; when providing antenatal genetic services, document counseling encounters using appropriate diagnosis codes.

• Use Z31.5 (Encounter for procreative genetic counseling) where applicable.
• Document counseling encounters and include appropriate ICD‑10 codes on claims.

Document counseling and provider qualifications when ordering NIPT

Offer NIPT with informed consent and counseling by a qualified provider and document the counseling; policy recommends that testing be ordered in settings with personnel qualified to provide pre‑ and post‑test counseling.

• Document provider qualifications and counseling provided when ordering NIPT.
• Ensure CLIA‑certified laboratory processing and counseling availability are in place.

No explicit ordering clinician restrictions; prenatal providers commonly order NIPT

No explicit restriction on which clinician may order NIPT is stated in the policy; prenatal care providers commonly order cfDNA screening, but referral to genetics is recommended for positive or complex results.

• Prenatal care providers may order cfDNA screening after appropriate counseling.
• Refer positive or ambiguous results to genetic counseling for further management.

No specialty restrictions; refer to genetic counseling for positives

The policy does not specify provider specialty restrictions for ordering NIPT; ensure positive or complex results prompt referral to genetic counseling for follow‑up.

• Document referrals to genetic counseling for positive or nonreportable results.
• Providers ordering NIPT should ensure counseling resources are available.

Contract dependency — verify product coverage before ordering

Services and coverage decisions are contract dependent; ordering/provider qualifications are not explicitly stated in the policy and eligibility should be confirmed with the member's product.

• Confirm that the member's product covers the requested service prior to ordering.
• If a product does not cover a service, the medical policy criteria do not apply.